CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands.
During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development services, will chair a discussion featuring external quality leaders from the CDMO industry. The talk will explore approaches for transforming quality management from a potential bottleneck into a strategic driver of CDMO partnerships. Ms. Klecker is well-positioned to lead the discussion based on her more than 30 years of industry experience in quality, manufacturing, and development, including guiding Lifecore’s quality assurance for over a decade.
Details regarding the discussion are as follows:
To learn more about the CDMO Live 2025 conference, please visit: https://pharmasource.global/events/cdmolive/
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Last Trade: | US$7.68 |
Daily Change: | -0.01 -0.13 |
Daily Volume: | 149,821 |
Market Cap: | US$284.390M |
June 17, 2025 April 03, 2025 January 07, 2025 January 02, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load